Pharmacogenomics of Rivaroxaban: Association of CYP3A4, CYP3A5, CYP2J2, ABCB1, and ABCG2 Variants with Bleeding and Thrombotic Outcomes in Real-World Clinical Practice
Pharmaceutics · 20.07.2026 · 18 (7) · 884
DOI: 10.3390/pharmaceutics18070884 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.07.2026. Verfasst von Ana Marija Slišković und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation.
Abstract (Originalsprache)
Aim
To evaluate associations between polymorphisms in CYP3A4 (*1B, *22), CYP3A5 (*3), CYP2J2 (*7, rs11572325), ABCB1 (c.1236C>T, c.2677G>T/A, c.3435C>T, rs4148738) and ABCG2 (c.421C>A) and the occurrence of bleeding or occlusive events in patients receiving rivaroxaban in real-world clinical practice.
Methods
A nested case-control study, divided into two substudies (bleeding and thromboembolic events), was conducted within a prospective cohort of 385 adults receiving rivaroxaban at University Hospital Centre Zagreb (September 2021–September 2024). Bleeding events were classified per ISTH criteria, and genotyping was performed using TaqMan real-time PCR. Cases and controls were balanced using entropy balancing, and associations were estimated with Bayesian logistic regression under a skeptical prior N(0, 0.355); LASSO regression was used to identify clinical and genetic predictors of outcomes.
Results
In total, 71 patients (18.4%) experienced bleeding events, most frequently gastrointestinal (47.9%), while 314 patients served as controls. No pharmacogenomic variant showed a clear association with bleeding risk (raw and balanced odds ratios 0.80–1.35; 95% credible intervals crossing 1.0). LASSO regression identified age (OR 2.00 per decade), gastrointestinal comorbidity (OR 8.77), and eGFR as the dominant predictors of bleeding. Twenty-one patients experienced occlusive events (15 venous, 6 arterial); however, the low event count precluded meaningful pharmacogenomic analysis.
Conclusions
Individual pharmacogenomic variants in CYP3A4, CYP3A5, CYP2J2, ABCB1, and ABCG2 together with pharmacogenetic-based phenotypes were not associated with clinically relevant bleeding in rivaroxaban-treated patients. Traditional clinical risk factors, particularly advanced age and gastrointestinal comorbidity, remain the dominant determinants of adverse outcomes. Routine pharmacogenomic testing to guide rivaroxaban dosing is not currently supported.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
- Department of Basic and Clinical Pharmacology, University of Zagreb School of Medicine, 10000 Zagreb, Croatia.
- Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
- Department of Medical Chemistry, Biochemistry and Clinical Chemistry, University of Zagreb School of Medicine, 10000 Zagreb, Croatia.
- Department of Internal Medicine, University of Zagreb School of Medicine, 10000 Zagreb, Croatia.
- Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
ORCID-Profile: Ana Marija Slišković, Vladimir Trkulja, Tamara Božina, Vedran Pašara, Majda Vrkić Kirhmajer, Dominik Strikić, Marino Narančić, Ivana Sopek Merkaš, Iveta Merćep, Joško Bulum, Livija Šimičević
Förderung
- Croatian Science Foundation
Zitieren
APA
Slišković, A. M., Trkulja, V., Ganoci, L., Božina, T., Pašara, V., Vrkić Kirhmajer, M., Palić, J., Strikić, D., Narančić, M., Sopek Merkaš, I., Merćep, I., Bulum, J., & Šimičević, L. (2026). Pharmacogenomics of Rivaroxaban: Association of CYP3A4, CYP3A5, CYP2J2, ABCB1, and ABCG2 Variants with Bleeding and Thrombotic Outcomes in Real-World Clinical Practice. Pharmaceutics, 18(7), 884. https://doi.org/10.3390/pharmaceutics18070884
Vancouver
Slišković AM, Trkulja V, Ganoci L, Božina T, Pašara V, Vrkić Kirhmajer M, et al. Pharmacogenomics of Rivaroxaban: Association of CYP3A4, CYP3A5, CYP2J2, ABCB1, and ABCG2 Variants with Bleeding and Thrombotic Outcomes in Real-World Clinical Practice. Pharmaceutics. 2026;18(7):884. doi:10.3390/pharmaceutics18070884
BibTeX
@article{Slikovi2026,
author = {Slišković, Ana Marija and Trkulja, Vladimir and Ganoci, Lana and Božina, Tamara and Pašara, Vedran and Vrkić Kirhmajer, Majda and Palić, Jozefina and Strikić, Dominik and Narančić, Marino and Sopek Merkaš, Ivana and Merćep, Iveta and Bulum, Joško and Šimičević, Livija},
title = {Pharmacogenomics of Rivaroxaban: Association of CYP3A4, CYP3A5, CYP2J2, ABCB1, and ABCG2 Variants with Bleeding and Thrombotic Outcomes in Real-World Clinical Practice},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {7},
pages = {884},
doi = {10.3390/pharmaceutics18070884}
}
EUVIMED